Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

181
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
181
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

280
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
280

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 2026 Multisociety Acute Pulmonary Embolism Guidelines: An Expert Perspective.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Machine Learning in Postcardiotomy Shock: Implications for Temporary Mechanical Circulatory Support.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

To Intervene or Not to Intervene: Rethinking Non-culprit Vessels in Acute Coronary Syndrome.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Atrial Functional Mitral Regurgitation: Contemporary Mechanisms, Imaging, and Perioperative Implications for Cardiothoracic Anesthesiologists and Intensivists.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Cardiogenic Shock: Current Evidence, Guideline Perspectives, and Outcomes.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

The Contemporary Landscape of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation.

Journal of cardiothoracic and vascular anesthesia·2026

Related Experiment Video

Updated: Dec 9, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.2K

Left Ventricular Mechanical Circulatory Support-Assessing Outcomes With New Data.

Kristin Stawiarski1, Harish Ramakrishna2

  • 1Department of Cardiology, Yale New Haven Health System, Bridgeport, CT.

Journal of Cardiothoracic and Vascular Anesthesia
|September 14, 2020
PubMed
Summary

Left ventricular assist devices (LVADs) are crucial for advanced heart failure. Recent advancements show LVADs evolving from temporary solutions to long-term destination therapy, improving quality of life and device durability.

Keywords:
Heart failureLVADSOutcomes

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.9K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K

Related Experiment Videos

Last Updated: Dec 9, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.9K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K

Area of Science:

  • Cardiology
  • Medical Devices
  • Surgical Technology

Background:

  • Ventricular assist devices (VADs) are vital in managing advanced heart failure.
  • Left ventricular assist devices (LVADs) have undergone significant technological and design improvements.

Purpose of the Study:

  • To review key data from the past 5 years on the evolution of LVADs.
  • To highlight the shift in LVAD application from bridge-to-transplantation to destination therapy.
  • To emphasize the growing focus on quality-of-life and durability.

Main Methods:

  • Literature review of published data over the last 5 years.
  • Analysis of trends in LVAD design, technology, implantation, and patient outcomes.
  • Focus on studies demonstrating the transition to destination therapy and quality-of-life improvements.

Main Results:

  • LVAD technology has rapidly evolved, enhancing patient outcomes.
  • The primary use of LVADs has shifted towards destination therapy.
  • Increased emphasis on improving patient quality of life and device longevity.

Conclusions:

  • LVADs are increasingly used as a long-term solution for heart failure.
  • The evolution of LVADs offers improved quality of life and durability for patients.
  • Future research should continue to focus on optimizing LVAD therapy for advanced heart failure management.